文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

延长半衰期RSV单克隆抗体预防免疫所需接种人数

Number needed to immunize to prevent RSV with extended half-life monoclonal antibody.
PubMed 文献 · Vaccine · 2020-06-26

研究结合RSV住院、门诊及下呼吸道感染发病率估计和多种免疫效力,用所需接种人数(NNI)模型评估延长半衰期RSV单克隆抗体的公共卫生获益。结果显示,70%效力下预防一次RSV相关门诊就诊需接种6–18名婴儿,预防一次住院在0–5月龄需37–85名、6–11月龄需107–280名。中等效力的EHL-mAb可能产生较大影响。

要点

  • 70%效力EHL-mAb预防一次RSV门诊就诊需接种6–18名婴儿。
  • 预防一次RSV住院,0–5月龄需接种37–85名,6–11月龄需107–280名。
  • 中等效力EHL-mAb可为公共卫生决策提供重要参考。

核心结论

  • 中等效力的RSV EHL-mAb可能具有较高公共卫生影响,NNI数据可为公共卫生决策提供额外视角。

研究设计与样本

  • 建模研究,结合RSV住院、门诊和门诊下呼吸道感染发病率估计及一系列免疫效力,计算年度NNI。

主要发现

  • 70%效力下,预防一次RSV相关门诊就诊需接种6–18名婴儿。
  • 70%效力下,预防一次RSV相关下呼吸道感染门诊就诊需接种13–33名婴儿。
  • 70%效力下,预防一次RSV相关住院,0–5月龄需接种37–85名婴儿,6–11月龄需接种107–280名婴儿。

关键数值与推荐

  • NNI按绝对发病率下降(ARR)的倒数计算,ARR由发病率乘以免疫效力得出。
  • 示例采用70%效力的RSV EHL-mAb进行估算。

临床怎么用

  • 可将NNI作为评估RSV EHL-mAb纳入国家免疫规划的公共卫生获益参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory syncytial virus (RSV) is one of the most important respiratory pathogens in young children. Infants <6 months of age and infants and young children with extreme pre-term birth, and cardiac and pulmonary co-morbidities experience the highest incidence of severe RSV disease. There are no licensed vaccines; immunoprophylaxis is recommended for the highest risk children. Extended half-life RSV monoclonal antibodies (EHL-mAbs) are under development intended for immunization of all infants and high-risk children <2 years of age. We modeled the anticipated public health benefits of RSV EHL-mAb immunization using the number needed to immunize (NNI). METHODS: We combined RSV hospitalization, outpatient and outpatient lower respiratory tract infection (LRI) incidence estimates and a range of immunization efficacies to estimate the annual NNI. We calculated the absolute incidence rate reduction (ARR) by multiplying the incidence rates by immunization efficacy. NNI was calculated as the reciprocal of the ARR. RESULTS: For an RSV EHL-mAb with 70% efficacy, 6-18 infants would need to be immunized to prevent one RSV-associated outpatient visit, and 13-33 infants would need to be immunized to prevent one RSV-associated LRI outpatient visit. To prevent one RSV-associated hospitalization, 37-85 infants 0-5 months of age, and 107-280 infants 6-11 months of age would need to be immunized. CONCLUSIONS: Public health benefits, such as disease cases averted due to immunization, are essential elements in consideration of candidate vaccines for a national immunization program. An RSV EHL-mAb of moderate efficacy could have high impact. These data provide an additional perspective for public health decision making.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Finelli L, Choi Y, Goldstein E, et al. Number needed to immunize to prevent RSV with extended half-life monoclonal antibody. Vaccine. 2020. PMID: 32600912. doi:10.1016/j.vaccine.2020.06.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。